目的探讨丹参酮ⅡA磺酸钠联合依达拉奉治疗急性脑梗死的临床疗效及安全性。方法选取100例急性脑梗死患者,随机数字表法分为两组,对照组患者（50例）给予依达拉奉治疗,观察组患者（50例）给予丹参酮ⅡA磺酸钠联合依达拉奉治疗,均治疗14 d。观察并记录两组患者治疗后1个月的疗效,治疗前后ESS评分、SF-36评分及治疗期间不良反应情况。结果治疗后,观察组有效率为90.0%,对照组有效率为72.0%,观察组治疗有效率明显高于对照组（P<0.05）。与治疗前相比,治疗后两组ESS评分均明显增加（P<0.05）,且观察组在治疗3、7、14 d的ESS评分均明显高于对照组（P<0.05）。治疗前两组SF-36各项得分相比,差异没有统计学意义；治疗后,两组SF-36各项得分均明显升高（P<0.05）,且观察组在生理功能、生理职能及精神健康上的评分高于对照组（P<0.05）。治疗期间,两组不良反应率无明显差异。结论丹参酮ⅡA磺酸钠联合依达拉奉对急性脑梗死具有较好的治疗作用,能改善患者神经功能,提高患者生活质量,用药具有安全性,值得临床推广使用。

Objective To discuss the efficacy and safety of sodium tanshinone ⅡA combined with edaravone in treatment of acute cerebral infarction. Methods 100 cases of acute cerebral infarction were randomly divided into two groups. The control group (50 cases) was treated with edaravone. The observation group (50 cases) was treated with sodium tanshinone ⅡA combined with edaravone. The efficacy of sodium tanshinone ⅡA combined with edaravone in treatment of acute cerebral infarction was evaluated by the efficacy at 1 month after treatment, ESS scores, SF-36 scores before and after treatment and adverse reaction during treatment. Results After treatment, the effective rate of observation group was 90.0% and control group was 72.0%. The effective rate of observation group was higher than that of the control group (P < 0.05). Compared with the value before treatment, the ESS scores of two groups were increased after treatment (P < 0.05). 3 d, 7 d, 14 d after treatment, the ESS scores of observation group was higher than that of the control group (P < 0.05). Before treatment, there were no statistical significance on SF-36 between two groups. After treatment, the SF-36 scores were increased in two groups (P < 0.05). During treatment, there were no statistical significance on adverse reaction between two groups. Conclusion Sodium tanshinone ⅡA combined with edaravone had a good therapeutic effect on acute cerebral infarction. It could improve the quality of life and neurological function with high safety. It was worthy of clinical application.